Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$13.81 USD

13.81
3,448,988

+1.32 (10.57%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $14.00 +0.19 (1.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why

Let us look at the factors that have led to the increase in share price of Emergent (EBS).

    Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?

    Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Inovio's Influenza Vaccine Shows Potential, Shares Rally

      Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.

        Exact Sciences (EXAS) in Focus: Stock Moves 5.1% Higher

        The shares of Exact Sciences (EXAS) rose over 5% yesterday.

          Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session

          Illumina (ILMN) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.

            Emergent Starts Phase II Study on Anti-influenza Candidate

            Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.

              5 Reasons to Pick Emergent as an Investment-Worthy Stock

              Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.

                Tirthankar Chakraborty headshot

                New Strong Buy Stocks for January 2nd

                Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                  2 Biotech Stocks with Month-Long Upward Estimate Revisions

                  Although the biotech sector initially picked up this year, it witnesses a correction since October. However, it is a good idea to select stocks witnessing positive estimate revisions for a month now.

                    Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now?

                    Peregrine Pharmaceuticals (PPHM) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and year.

                      David Bartosiak headshot

                      Five Marvelous Momentum Stocks to Buy Now

                      These five Zacks Rank #1 (Strong Buy) stocks are surging on huge demand and breaking higher

                        BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%

                        BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

                          Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

                          Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

                            Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

                            Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

                              What's in Store for Conatus (CNAT) This Earnings Season?

                              Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.

                                Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?

                                Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.

                                  Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit

                                  Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.

                                    Emergent Completes Acquisition of Anthrax Drug Raxibacumab

                                    Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.

                                      Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue?

                                      Emergent Biosolutions (EBS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        CVS Health (CVS) Releases Encouraging Flu Shot Survey Data

                                        CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.

                                          Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

                                          Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.

                                            Why Is Emergent Biosolutions (EBS) Up 3.9% Since the Last Earnings Report?

                                            Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              Emergent (EBS) Beats Earnings, Revenue Estimates in Q4

                                              Emergent BioSolutions, Inc. (EBS) reported earnings of 74 cents per share in the fourth quarter of 2016, which surpassed the Zacks Consensus Estimate of 60 cents. However, the reported figure decreased from 77 cents earned in the year-ago period.

                                                Emergent Down on '17 View, Posts Preliminary '16 Results

                                                Emergent announced better-than-expected preliminary 2016 results. However, the outlook for 2017 fell short of estimates.

                                                  5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices

                                                  For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.